New European limitations for restricted substances in medical devices are coming into force under the new REACH legislation.
For the first time, Medical Equipment will be included under the European Union’s RoHS legislation, the requirement to disclose Substances of Very High Concern (SVHC), and the inclusion of medical products in the Electronic Information Products (EIP) list [...]
Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding will resume patient enrollment and continue with no modifications.
Tags: aprotinin, biological components, biosurgery, clinical trial protocol, company [...]
Saving a life can be easy. Indeed, few people realize how easy it has become for the average person to intervene constructively in a cardiac emergency, where every second counts.
Automated external defibrillators, or AEDs, are being installed with growing frequency in public spaces such as offices, airports, and shopping centers, enabling bystanders with virtually no [...]
Deerfield Urethane, Inc. (Deerfield), a wholly owned subsidiary of Bayer MaterialScience LLC (BMS) and one of the leading suppliers of custom, made-to-order thermoplastic polyurethane (TPU) and specialty elastomer film and sheet, is proud to announce its collaboration with BHS International (BHS), a breast health company co-founded by Olivia Newton-John, in the development and production of [...]
Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding was suspended yesterday afternoon to investigate an incident of post-operative bleeding. The Company will provide an update once additional information is [...]
